Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2018 (2018), Article ID 2164312, 5 pages
https://doi.org/10.1155/2018/2164312
Case Report

Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody

1Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan
2Department of Pediatrics, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan

Correspondence should be addressed to Takako Miyamae

Received 1 September 2017; Revised 12 November 2017; Accepted 28 November 2017; Published 6 February 2018

Academic Editor: Mehmet Soy

Copyright © 2018 Takako Miyamae et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Tjarnlund, M. Bottai, L. G. Rider et al., “Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies,” Pediatric Rheumatology, vol. 12, no. 1, p. P94, 2014. View at Publisher · View at Google Scholar
  2. L. G. Rider, J. D. Katz, and O. Y. Jones, “Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies,” Rheumatic Disease Clinics of North America, vol. 39, no. 4, pp. 877–904, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. L. G. Rider and K. Nistala, “The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes,” Journal of Internal Medicine, vol. 280, no. 1, pp. 24–38, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Kobayashi, S. Takezaki, I. Kobayashi et al., “Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis,” Rheumatology, vol. 54, no. 5, pp. 784–791, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Tansley, Z. E. Betteridge, H. Gunawardena et al., “Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study,” Arthritis Research and Therapy, vol. 16, no. 4, p. R138, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Imokawa, T. V. Colby, K. O. Leslie, and R. A. Helmers, “Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients,” European Respiratory Journal, vol. 15, no. 2, pp. 373–381, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Goussot, A. Theulin, J. Goetz, J. Sibilia, J. E. Gottenberg, and A. Meyer, “An arthro-dermato-pulmonary syndrome associated with anti-MDA5 antibodies,” Joint Bone Spine, vol. 81, no. 3, p. 266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Hall, L. Casciola-Rosen, L. A. Samedy et al., “Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum,” Arthritis Care and Research, vol. 65, no. 8, pp. 1307–1315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. E. Petty, T. R. Southwood, P. Manners et al., “International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001,” Journal of Rheumatology, vol. 31, no. 2, pp. 390–392, 2004. View at Google Scholar
  10. K. Barut, P. O. Aydin, A. Adrovic, S. Sahin, and O. Kasapcopur, “Juvenile dermatomyositis: a tertiary center experience,” Clinical Rheumatology, vol. 36, no. 2, pp. 361–366, 2017. View at Publisher · View at Google Scholar · View at Scopus